Primary prevention of venous thromboembolic events (VTE) in cancer patients: An American survey study

8086 Background: Optimal care of and research involving cancer patients at risk for and with documented VTE require insight into thrombosis risk factors plus risks and benefits of anticoagulation (AC). Formal quantification of oncologist attitudes towards VTE has been lacking. Methods: We performed a two-phase, web- and fax-based survey study of American oncologists, including 28 questions that asked respondents to quantify the “necessity” and “appropriateness” of VTE prophylaxis or treatment in several clinical scenarios. Mean responses provided assessment of group opinion. Results: In Phase I (n=507), 61% and 63% indicated regular prescription of inpatient and central line VTE prophylaxis, respectively; 39% believed that LMWHs can prolong cancer patient survival. Phase II (n=112 from 33 states) demographics: 63% private practice, 84% solid tumor focus, 79% Oncology board certified, 88% ASCO members. Respondents under-recognized known VTE risk factors (e.g. brain mets, antiangiogenesis drugs, and EPO) an...